Post Menopausal Hormones - reduces risk of macular degeneration
Apr 14, 2008 - 1:52:27 PM
, Reviewed by: Dr. Sanjukta Acharya
|
|
|
“Taken together, these findings suggest a role for estrogen in the pathogenesis of AMD that requires further research in specific early and late signs of disease,” the authors conclude.
|
By JAMA and Archives Journals,
[RxPG] Women who take postmenopausal hormones appear to have a lower risk of developing advanced stages of the eye disease age-related macular degeneration, especially if they had also taken oral contraceptives in the past, according to a report in the April issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among older adults, affecting 1.75 million Americans, according to background information in the article. “Although genetics plays a key role in susceptibility to AMD, environmental factors, such as smoking, are also important,” the authors write. “Evidence of higher rates of AMD in women than in men and links between AMD and cardiovascular disease suggested a role for estrogen in the etiology” or development of the condition.
Diane Feskanich, Sc.D., of Brigham and Women’s Hospital and Harvard Medical School, Boston, and colleagues assessed estrogen-related factors such as postmenopausal hormone use, past use of oral contraceptives, ages at first period and menopause and childbirth history in 74,996 post-menopausal women in the Nurses’ Health Study. Between 1980 and 2002, 554 of the women developed early (beginning-stage) AMD and 334 women developed neovascular (more advanced, involving the formation of new blood vessels) AMD.
“Current postmenopausal hormone users had a notable 48 percent lower risk of neovascular AMD compared with those who had never used postmenopausal hormones, although risk did not decline linearly with longer durations of use,” the authors write. “Risk was lowest for postmenopausal hormone users who had used oral contraceptives in the past.”
In contrast, risk of early AMD was 34 percent higher among current postmenopausal hormone users and oral contraceptive use was not associated with early AMD risk. “The higher risk of early AMD among postmenopausal hormone users was unexpected and in apparent conflict with the observed inverse association for neovascular AMD,” the authors write. Women who had given birth had a 26 percent lower risk of early AMD.
“Taken together, these findings suggest a role for estrogen in the pathogenesis of AMD that requires further research in specific early and late signs of disease,” they conclude.
Publication:
April issue of Archives of Ophthalmology
|
| Funding information and declaration of competing interests:
This research was supported by grants from the National Institutes of Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to ARMD Newsletter
|
|
|
|
About Dr. Sanjukta Acharya
|
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
